Despite steady demand for obesity medications, 49% of payers who do not currently cover GLP-1s for obesity would not do so at any price, a new
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
The blockbuster success of GLP-1 weight loss drugs has caused major ripple effects across healthcare and pharma, representing a…
Drug spending is rising sharply, with high-cost GLP-1 medications driving nearly half of the incr | How RxSense helped a health…
The Trump administration has officially launched its new "bridge" model that brings GLP-1 coverage for weight loss to Medicare…
LAS VEGAS — As drug costs and spending continue to rise, the demand for solutions opens the door to closer collaboration between…
Healthcare costs continue to rise, making effective payer-provider collaboration more important than ever. Download this free…
Employers that have access to key data on their healthcare spending and costs are more likely to take steps to address…
